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ABSTRACT 
Most corporations seem geared to buy assets, not sell them. Estimates suggest 
corporations acquire three businesses for every one they divest (Mankins 2008). A 
corporation with a disciplined approach to divestiture seems more likely to sharpen 
strategic focus and deliver value to shareholders. This thesis defines and explores the 
concept of an orphan product as an opportunity for divestiture from a parent company and 
subsequent acquisition for a startup company.  
Orphan product is defined by reviewing literature and selecting the following 
criteria for a given product; the product has a lack of marketing support/focus, the product 
is not considered core to the parent company, product sales trend over a 5-year time frame 
is decreasing, cash flows are uncertain, market growth for the category the product 
competes in is smaller than the industry average, the product life cycle position is mature, 
and  portfolio synergy is low due to the parent company having other products that deliver 
similar benefits. A scorecard is developed and used to score orphan characteristics of four 
products in the animal health industry.  Two of the four products analyzed are classified as 
orphan products and therefore potential candidates for purchase by the startup company. 
A Strategy Canvas is developed and value curves are assigned per product to show 
how the startup company can market an acquired product relative to the critical success 
factors in the animal health industry (Kim and Mauborgne, 2005). A framework of critical 
questions is posed to each product resulting in recommendations for the startup on critical 
success factors to eliminate, reduce, raise, or create. For the orphan products, a 
recommendations include:  raise price, increase marketing support, and/or create new 
 
 
factors to differentiate such as to offer additional services or to develop pricing models that 
are simple and clear. Application of this research can be applied to companies seeking to 
acquire animal health products that would like to better understand how to improve their 
chances for success. 
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CHAPTER I: INTRODUCTION 
Most corporations seem geared to buy assets, not sell them (Mankins 2008). A 
corporation with a disciplined approach to divestiture seems more likely to sharpen 
strategic focus and deliver value to shareholders. This concept is supported by a study by 
Bain and Company completed in 2007 that analyzed 7,315 divestitures by 742 companies 
over a 20-year period. A finding in the study is that a company more focused on successful 
divestiture to return 80% more compared with companies not as focused in divestiture.  
Divestiture in the animal health industry fits the trend Mankins postulates regarding 
acquisition without offsetting divestiture. Mergers and acquisitions in the animal health 
industry often result in companies increasing the number of products in a given portfolio. A 
review of industry media  through the first three quarters of 2015 (Table 1.1) reports 24 
mergers or acquisitions with an estimated cumulative transaction value of $13 billion 
(USD). Four of the twenty-four transactions were for one product and the balance of the 
mergers were for entire divisions or product lines that encompass many products absorbed 
by the acquiring companies. Do the companies in this table have a divestiture strategy or do 
they plan on incorporating all new products into their existing portfolios? Is there a chance 
that some products in a portfolio are undervalued?  
This thesis explores the concept of an orphan product, an undervalued brand for 
divestiture consideration from a parent company and acquisition by a startup animal health 
company. Orphan products are defined, in this thesis by the essential characteristics such as 
attention from management and marketing investment. Prestige Brands (NYSE: PBH) is an 
example in the consumer goods industry applying an acquisition approach of orphan 
products. PBH identifies products that have strong consumer followings, but might not 
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have had adequate marketing focus or the capital resources to develop their full value. 
Products that PBH markets are typically not considered core by the parent company and 
typically do not benefit from the focus of senior-level management or have support from 
sales and/or marketing. PBH provides acquired brands with support and the requisite 
attention, resulting in an enhanced market position, expanded distribution, and successful 
launches of line extensions. Can this business concept be replicated in the animal health 
industry? What criteria could be applied to identify and select products to consider for 
acquisition?  
Table 1.1: Animal Health Industry Mergers and Acquisitions and Estimated 
Transaction Value, Q1-Q3 2015 (Source: Media Reports) 
Product(s), Company or 
Division Divested 
Divesting Firm Acquiring Firm Estimated Value 
(USD $, millions)
tagg Qualcomm Whitle Not Reported 
Abbott Animal Health  Abbott Labs Zoetis $255 
Big Heart Pet Products Big Heart Pet  J.M. Smucker $6,000 
N.F. Additives, Inc. N.F. Additives, Inc.  Petell M. and I. Not Reported 
Veterinary Supplies Jorgen Kruuse A/S Henry Schein $77 
Ridley Ridley Alltech Not Reported 
AHI AHI Patterson Co, Inc. $1,100 
Stering Test House Sterling Test House Neogen Not Reported 
VIP Petfoods (Aus) VIP Petfoods (Aus) Quadrant PE $314 
Golden Acres Gen. Golden Acres Gen. AgReliant Genetics Not Reported 
Produs AS Produs AS Alltech Not Reported 
Produs Aqua AS Produs Aqua AS Alltech Not Reported 
Maravet Maravet Henry Schein $12 
NoxiFerm Feed Supp. Unknown Brookside Agra Not Reported 
KL Products KL Products Zoetis Not Reported 
ANC An. Nut. ANC An. Nut. Huvepharma Not Reported 
Teva Products Bayer Bayer $145 
Diagnostic Products Scil Animal Care Henry Schein $70 
Autogenous Vaccines Gallant Custom Lab. IDT Biologika Not Reported 
Veterinary Division ESTEVE Ecuphar Not Reported 
MJ Biologicals MJ Biologicals PhiBro Not Reported 
IZO S.r.l. IZO S.r.l. Vaxxinova GmbH Not Reported 
Sentinel Elanco Virbac $410 
Novartis Animal Health Novartis Elanco (Lilly) $5,400 
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1.1 Research Problem  
As portfolios expand from activities such as acquisition, companies are required to 
either stretch investment dollars to support more products, gain more investment dollars to 
spread over products, or focus on only supporting a few core products (Alexander and 
Francis 1986). Alexander and Francis make the case that product deletion for firms is 
difficult, citing a major driver as the uninspiring nature of product deletion contrasted with 
the excitement of higher profile projects such as product launches, which often compete for 
a manager’s time. Alexander and Francis call for companies to set up a procedure for 
deletion of products. This thesis builds on Alexander’s thoughts that companies are 
reluctant to divest products from their portfolio and recognizes that there are orphan 
products in the animal health industry that are undervalued. The purpose of this thesis is, 
therefore, to answer the following key questions:  
1. What are the key characteristics of orphan products?  
2. How may orphan products be identified in a given portfolio of products? 
3. If an animal health startup company purchases an orphan product, how could it 
market the product to be successful?    
1.2 Research Objectives  
 This research is conducted from the perspective of a startup company looking to 
identify, purchase, and market an orphan product. The overall objective is to develop a tool 
that identifies orphan products and to provide a tool to guide strategic decisions the startup 
must make to ensure success. To address these issues, this thesis will meet the following 
objectives:  
1. Define the characteristics of orphan products that may be applicable in any 
industry or company 
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2. Develop a tool to objectively define and identify orphan products  
3. Apply the Strategy Curve/Value Canvas methodology to guide strategic 
decisions to the startup company with regards to marketing a newly 
acquired orphan product  
1.3 Methods 
An  orphan product definition will be crafted by reviewing literature for product 
traits. A scorecard method is developed based on the criteria embedded in the orphan 
product definition to apply to products that will classify them as “orphan” or “not orphan.” 
The Strategy Canvas/Value Curve approach is applied products identified as orphans to 
provide guidance to the startup company regarding critical success factors in the animal 
health industry that will need to be managed (Kim and Mauborgne 2005).  
1.4 Layout of the  Research  
This chapter made the case that there are orphan products in the animal health 
industry due to portfolio expansions and the lack of offsetting and active divestiture 
activity. Chapter 2 will provide a review of literature resulting in a definition of orphan 
product. The definition of orphan product will be used to create a scorecard, with 
guidelines for use to evaluate products. Chapter 3 will evaluate four products in the animal 
health industry via the developed scorecard. For products identified as orphans, their value 
curves will be plotted on a Strategy Canvas to demonstrate how the startup can successfully 
manage an orphan product after it is acquired.  Chapter 4 will summarize the research and 
how the research can be applied.   
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CHAPTER II: LITERATURE REVIEW 
2.1 Defining an Orphan Product 
The definition of orphan product in the context of this thesis should not be confused 
with the orphan drug concept that is formalized through the Orphan Drug Act (ODA) 
administered by the Food and Drug Administration (FDA). The ODA grants special status 
for a drug or biological product to treat a rare disease or condition upon request of a 
sponsor. Orphan drug designation qualifies the developer of the drug various incentives and 
generally is a way to ensure medications are developed to address disease concerns that 
otherwise (based on the merits of profitability analysis alone) might not come to market. 
This thesis will introduce the concept of orphan product defined as the result of a literature 
review and interviews with product managers and is meant to classify products in the 
animal health industry relative to the amount of focus provided to the product by the parent 
company.  
2.2 Orphan Product Traits 
The descriptor orphan product does not appear consistently in literature. The firm 
PBH cites its strategy is to identify and acquire  “under-valued products” (Prestige Brands 
Holdings, Inc. 2005). PBH goes on to explain how they target product to add to their 
portfolio “We identify brands that have strong consumer followings, but may not have had 
adequate marketing focus….in many cases, these brands were considered non-core….and 
did not benefit from the focus of senior level management or strong brand-marketing 
support” (Prestige Brands Holdings, Inc. 2005, 2).  This description initiates the definition 
of an orphan brand, by revealing the following traits for consideration (i) not adequate 
focus and support from marketing and senior management and (ii) product not considered 
core to the company. Traits like the ones listed by PBH as guidelines to follow when 
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looking for brands to purchase do not seem revealed in literature. Due to the lack of 
guidelines suggesting what traits an acquiring company should pursue, a literature review is 
completed looking for information on product divestiture strategy. It should be noted that 
most literature refers to A summary of this information is presented in Table 2.1.  
Table 2.1 Divestiture recommendations in literature   
Brand or Product Divestiture 
Guidance  
Source 
Marketing support and focus is 
low 
PBH Annual Report  
Divest if product sales over time 
are declining  
Shell Directional Policy Matrix (DPM)  
Divest if cash flow is uncertain  DPM 
Divest if market growth is low  DPM 
Divest if the product is in a low 
growth market segment  
DPM 
Divest if the product life cycle 
position is mature  
Product Performance Matrix 
Divest if there is redundancy in the 
portfolio  
Dranikoff 
Divest when products enter the 
sales decline stage 
Cox  
Divest when products do not meet 
internal NPV, IRR, or ROI 
benchmarks 
Evans, Matheson, et al.  
Divest when products have low 
growth rate and relatively low 
market share 
Boston Consulting Group BCG Matrix (Bruce 
Henderson) 
Divest when there are product 
overlaps regarding functionailty 
Vu et al.  
  
This literature review has resulted in multiple traits to consider for defining an 
orphan product. Many of the traits found in this literature are consistent with previous, 
extensive literature reviews on brand, and product, divestiture (Dung 2012). As a result of 
the review, the following is proposed as an orphan product definition:  
An orphan product is one that, has low marketing support/focus, is declining in 
sales, has uncertain cash flow, is competing in a market with low growth, is 
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competing in segment with low growth, is mature in its product life cycle, is 
redundant in a portfolio, does not meet company financial standards, and has low 
market share.  
 
2.3 The Strategy Canvas and Value Curve  
The strategy canvas and value curve are concepts introduced to serve as a 
diagnostic and action framework for building strategy (Kim and Mauborgne 2005). The 
strategy canvas communicates where competitors for a given product are current investing. 
What factors are competitors competing on with regards to service, delivery, product 
features, marketing, etc? The strategy canvas captures these characteristics on a two 
dimensional graph, with the competitive factors serving as the horizontal axis. For this 
thesis, factors are developed based on the specific products being analyzed, and include 
items such as marketing focus, the safety profile of the product, and technical services 
support, to name a few.  
The vertical axis of the strategy canvas is an indication of the offering level that the 
buyer of a product being analyzed would receive across all the competitive factors listed. 
When analyzing a specific product, the value curve for the product is created by 
considering how much value (what offering level) a customer is receiving relative to the 
competitive factor on the horizontal axis. This mapping of a products features provides a 
graphic depiction of a company’s performance relative to forces of competition in the 
industry.  
2.4 The Four Actions Framework and ERIC Grid  
The Four Actions Framework is a series of questions that have been developed to 
understand trade-offs made regarding investments in competitive factors for a given 
product (Kim and Mauborgne 2005). The questions posed in the Four Actions Framework 
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are asked relative to the factors of competition that are listed on the strategy canvas. The 
questions are: (i) what factors of the industry that my product competes on should be 
eliminated? (ii) which factors should be reduced below the industry standard?, (iii) which 
factors should be increased, or raised above the industry standard?, and (iv) which factors 
should be created that the industry does not offer? 
The ERRC Grid is a supplemental analytic tool to the Four Actions Framework that 
is intended to provide direction on what actions can be taken to differentiate a product by 
creating new forms of value to offer to customers (Kim and Mauborgne 2005). The ERRC 
grid is adjusted very slightly for this thesis, and is referred to as an “ERIC” grid – replacing 
the “Raise” component of ERRC with an “I” for “Increase.” 
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CHAPTER III: METHODS  
3.1 Orphan product scorecard  
 Applying the orphan product definition to actual products in the industry to identify 
if they are orphans, or not – a score card is developed (Table 3.1). 
Table 3.1 Orphan Product Scorecard  
Orphan Product 
Criteria 
0 score 1 score  
Marketing support and 
focus is low  
Some marketing support No marketing support 
Product sales over time 
are declining  
5-year sales trend is flat 
or increasing   
5-year sales trend is declining 
Cash flow is uncertain Consistently positive 
cash flow  
Periods of cash flow rotating 
between positive and negative  
Market growth is low  Market growth higher 
than GDP growth 
Marketing growth lower than 
GDP growth 
Market segment growth is 
low 
Market segment growing 
faster than the industry 
average 
Market growth growing lower 
than the industry average 
Product life cycle position 
is mature 
Product is increasing 
sales at an increasing rate 
Product is increasing sales at a 
decreasing rate 
Product is redundant in a 
portfolio 
Unique product offering Redundant offering in a 
portfolio  
Product does not meet 
company NPV, IRR, or 
ROI standards 
Does not meet companies 
started benchmark 
Does meet companies stated 
benchmark 
Product has low growth 
rate and low market share 
Product is growing faster 
than growth for the 
segment it competes in 
and market share is equal 
or greater than 
competitors  
Product growth lower than the 
growth for the segment it 
competes in and market share 
is lower than key competitors 
 
The score card includes traits that were found in the literature review and provides 
guidelines for the start up to apply, to rank the product being analyzed relative to the trait 
being considered. Of the ten traits found in the literature review, there are several that are 
very similar, and therefore consolidated on the score card. For example, Vu cites that a 
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product should be considered for divestiture if it overlaps functionality with another 
product in a company’s portfolio. Similarly, Dranikoff suggests divestiture if a product is 
deemed redundant in a portfolio from a similar, functionality standpoint. Due to these traits 
being so similar, they are blended together into one criteria on the score card, “Portfolio 
Redundancy”. Additional trait consolidations made for the scorecard are: (i) combining the 
DPM criteria “Divest if product sales over time are declining” with the criteria from Cox 
“Divest when products enter the sales decline stage”, and (ii) combining Vu’s “Divest 
when there are product overlaps regarding functionality” with Dranikoff’s “Divest if there 
is redundancy in the portfolio.” Guidelines for awarding a product score of zero or one are 
provided in Table 3.1.  
Four products are selected to be scored for their orphan product score. Two of the 
products (Vaccine A, and Injectable Antibiotic A) are scored in conjunction with an 
interview with a Product Manager affiliated with the products. The identity of the manger, 
products, and parent company are kept confidential. The remaining two products analyzed 
are Deccox®, a medicated feed additive manufactured by Zoetis, and ReaShure® an 
encapsulated protein product fed to dairy cattle, manufactured by Balchem. These products 
because they were owned by publicly traded companies with annual reports that can 
provide evidence to support assertions made during the orphan product scoring process.  
3.2 Orphan Product Scoring: Vaccine A  
Vaccine A is a product used in the bovine industry to help prevention of disease. 
The product was launched in the mid-90s and is one product in a portfolio of four other 
products that help address a similar disease as this Vaccine. The scoring for Vaccine A was 
conducted with a product manager who formerly managed the product. The vaccine scored 
a 5 with score details shown in Table 3.2.  
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Table 3.2 Orphan Product Scorecard Vaccine A 
Orphan Product 
Criteria 
0 score 1 score  Vaccine A Score 
Marketing support 
and focus is low  
Some marketing 
support  
No marketing support 
 
1 
Product sales over 
time are declining  
5-year sales trend is 
flat or increasing   
5-year sales trend is 
declining 
1 
Cash flow is 
uncertain 
Consistently 
positive cash flow  
Periods of cash flow 
rotating between 
positive and negative  
0 
Market growth is 
low  
Market growth 
higher than GDP 
growth 
Market growth lower 
than GDP growth 
0 
Market segment 
growth is low 
Market segment 
growing faster than 
the industry 
average 
Market growth growing 
lower than the industry 
average 
0 
Product life cycle 
position is mature 
Product is 
increasing sales at 
an increasing rate 
Product is increasing 
sales at a decreasing 
rate 
1 
Product is 
redundant in a 
portfolio 
Unique product 
offering 
Redundant offering in a 
portfolio  
1 
Product does not 
meet company 
NPV, IRR, or ROI 
standards 
Does not meet 
companies started 
benchmark 
Does meet companies 
stated benchmark  
0 
Product has low 
growth rate and 
low market share 
Product is growing 
faster than growth 
for the segment it 
competes in and 
market share is 
equal or greater 
than competitors  
Product growth lower 
than the growth for the 
segment it competes in 
and market share is 
lower than key 
competitors 
1 
Total Score   5 
 
The vaccine brand scored is one brand in a family of ten, therefore the Product 
Manager reports this brand does not get marketing support and is scored a one. Product 
sales over time are decreasing and are scored a zero. Cash flow is reported by the product 
manager as consistent and is scored a zero. Market growth for the segment the vaccine 
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competes in is reported at 5 percent. GDP growth is assumed to be 1.5 percent (Real GDP 
Growth reported on the U.S. Bureau of Economics website 11/18/2015) and therefore 
Vaccine A is scored a zero. The segment that the vaccine competes in is growing at 5 
percent and the animal health industry is assumed to be growing at 4 percent, hence a 0 
score. The sales for Vaccine A are reported to be increasing at a decreasing rate, resulting 
in a 1 score on the product maturity criteria. Vaccine A is one of many products in a 
portfolio that address a similar disease pathogen, hence a 1 score is given for portfolio 
redundancy. The product manager reports that the vaccine meets the ROI benchmark that 
the parent company uses to analyze performance and is therefore scored a 0. The product is 
reported as growing at a rate slower than the market segment it competes in, and is reported 
as losing market share, hence a 1 score on the appropriate criteria.  
3.3 Orphan Product Scoring: Deccox® 
The scoring for Deccox was conducted based on analysis of available information 
accessible via the public domain. Deccox is a medicated feed additive fed to poultry and 
cattle producers to prevent an enteric disease called coccidiosis. For this analysis, Deccox 
was considered for its usage in the cattle industry. Deccox scored a 6 and the details of the 
score are reported in Table 3.3.  
Table 3.3 Orphan Product Scorecard Deccox 
Orphan Product 
Criteria 
0 score 1 score  Deccox Score 
Marketing support 
and focus is low  
Some marketing 
support  
No marketing support 
 
1 
Product sales over 
time are declining  
5-year sales trend is 
flat or increasing   
5-year sales trend is 
declining 
0 
Cash flow is 
uncertain 
Consistently 
positive cash flow  
Periods of cash flow 
rotating between 
positive and negative  
0 
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Market growth is 
low  
Market growth 
higher than GDP 
growth 
Market growth lower 
than GDP growth 
0 
Market segment 
growth is low 
Market segment 
growing faster than 
the industry 
average 
Market growth growing 
lower than the industry 
average 
1 
Product life cycle 
position is mature 
Product is 
increasing sales at 
an increasing rate 
Product is increasing 
sales at a decreasing 
rate 
1 
Product is 
redundant in a 
portfolio 
Unique product 
offering 
Redundant offering in a 
portfolio  
1 
Product does not 
meet company 
NPV, IRR, or ROI 
standards 
Does not meet 
companies started 
benchmark 
Does meet companies 
stated benchmark 
0 
Product has low 
growth rate and 
low market share 
Product is growing 
faster than growth 
for the segment it 
competes in and 
market share is 
equal or greater 
than competitors  
Product growth lower 
than the growth for the 
segment it competes in 
and market share is 
lower than key 
competitors 
0 
Total Score   4 
 
Marketing support and focus was given a 1 score based on a search of two websites 
(www.agweb.com and www.cattlenetwork.com) and three key print publications (Hoard’s 
Dairyman, Calf News, and Drover’s) reviewed little to no specific advertisements or public 
relations on Deccox in the previous 12 month period. Product sales over time are assumed 
to be increasing. While do data is publicly available to support this trend, the global 
forecast for an increase in anticoccidial drugs to increase is assumed to translate to 
increased sales for Deccox (Research and Markets 2014). Cash flow certainty is scored a 0 
based on an assumption that medicated feed additives have steady and consistent 
production costs and pricing discipline. Market growth for the anticoccidial market is 
scored a 0 based on reports of 3.4 percent growth for anticoccidial medications, which is 
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higher than reported GDP growth (Research and Markets 2014). As previously cited, the 
anticoccidial market is experiencing 3.4 percent growth which is less than the 4 percent 
growth assumed for the animal health industry, resulting in a 1 score for this criteria 
(Research and Markets 2014).  Product lifecycle position is scored as a 1 since Deccox was 
launched in the mid-1990s for cattle and is determined to be past introduction and rapid 
growth phase. Product redundancy is scored as a 1, since Zoetis has another product in its 
portfolio that has an indication for use for coccidiosis control (Bovatec®, lasalocid). Deccox 
is assumed to be meeting company NPV, IRR, or ROI standards and scored a 0. Deccox is 
scored a 0 on low market growth rate and low market share, despite the previously reported 
anticoccidial market growth being lower than animal health industry growth. Without being 
able to know for certain via publicly available information the status of Deccox market 
share a 0 score is provided.  
3.4 Orphan Product Scoring: Injectable Antibiotic A 
The scoring for Injectable Antibiotic A was conducted with a Product Manager 
formerly affiliated with the company that manages the product. The product and company 
are kept confidential. The antibiotic scored a 1 and details are provided in Table 3.4.  
Table 3.4 Orphan Product Scorecard Injectable Antibiotic A  
Orphan Product 
Criteria 
0 score 1 score  Injectable 
Antibiotic A 
Score 
Marketing support 
and focus is low  
Some marketing 
support  
No marketing support 
 
0 
Product sales over 
time are declining  
5-year sales trend is 
flat or increasing   
5-year sales trend is 
declining 
0 
Cash flow is 
uncertain 
Consistently 
positive cash flow  
Periods of cash flow 
rotating between 
positive and negative  
0 
Market growth is 
low  
Market growth 
higher than GDP 
growth 
Market growth lower 
than GDP growth 
0 
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Market segment 
growth is low 
Market segment 
growing faster than 
the industry 
average 
Market growth growing 
lower than the industry 
average 
0 
Product life cycle 
position is mature 
Product is 
increasing sales at 
an increasing rate 
Product is increasing 
sales at a decreasing 
rate 
1 
Product is 
redundant in a 
portfolio 
Unique product 
offering 
Redundant offering in a 
portfolio  
0 
Product does not 
meet company 
NPV, IRR, or ROI 
standards 
Does not meet 
companies started 
benchmark 
Does meet companies 
stated benchmark 
0 
Product has low 
growth rate and 
low market share 
Product is growing 
faster than growth 
for the segment it 
competes in and 
market share is 
equal or greater 
than competitors  
Product growth lower 
than the growth for the 
segment it competes in 
and market share is 
lower than key 
competitors 
0 
Total Score   1 
 
Marketing support and focus is high based on a search for product advertisements 
on the same websites and print media analyzed previously Deccox.  Product sales are 
increasing above the rate of the market and therefore are scored at a zero. Cash flows are 
reported as consistent, translating to a 0 score. The product manager reports the growth for 
this segment and product are both above the GDP, industry, and segment growth rates, 
resulting in 0 scores for those criteria. The product is in the late growth phase of its launch 
and therefore is scored as a 1 and was confirmed by the product manager as having 
increasing revenue growth at a decreasing rate. Product redundancy is scored a 0 since the 
product in unique to the portfolio the parent company offers. The product is reported to 
meet all company NPV, IRR, and/or ROI type metrics. The product growth rate and market 
share are both equal and greater than competitors and therefore scored a 0.  
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3.5 Orphan Product Scoring: Reashure® Choline 
The scoring for Reashure Choline was conducted based on publicly available 
information.  Reashure scored a 3 and details of the score are reported in Table 3.5.  
Table 3.5: Orphan Product Scorecard: Reashure Choline   
Orphan Product 
Criteria 
0 score 1 score  Reashure Score 
Marketing support 
and focus is low  
Some marketing 
support  
No marketing support 
 
0 
Product sales over 
time are declining  
5-year sales trend is 
flat or increasing   
5-year sales trend is 
declining 
0 
Cash flow is 
uncertain 
Consistently 
positive cash flow  
Periods of cash flow 
rotating between 
positive and negative  
0 
Market growth is 
low  
Market growth 
higher than GDP 
growth 
Market growth lower 
than GDP growth 
0 
Market segment 
growth is low 
Market segment 
growing faster than 
the industry 
average 
Market growth growing 
lower than the industry 
average 
0 
Product life cycle 
position is mature 
Product is 
increasing sales at 
an increasing rate 
Product is increasing 
sales at a decreasing 
rate 
1 
Product is 
redundant in a 
portfolio 
Unique product 
offering 
Redundant offering in a 
portfolio  
0 
Product does not 
meet company 
NPV, IRR, or ROI 
standards 
Does not meet 
companies started 
benchmark 
Does meet companies 
stated benchmark  
1 
Product has low 
growth rate and 
low market share 
Product is growing 
faster than growth 
for the segment it 
competes in and 
market share is 
equal or greater 
than competitors  
Product growth lower 
than the growth for the 
segment it competes in 
and market share is 
lower than key 
competitors 
0 
Total Score   3 
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 Marketing support is scored a 1 based on analysis of the same web and print media used the 
other products analyzed that resulted in recent marketing information for Reashure Choline 
appearing in the previous 12-month period.  Product sales over time declining is scored a 0 
because due to information in the Annual Report that cites growth for the Reashure 
product. Cash flow is scored a as a 0 since the cash flow statement on the Balchem Annual 
Report shows consistently positive cash flow, therefore it is assumed that the actual product 
would be managed in a consistent manner. Market growth for the animal health space is 
higher than Real GDP so this criteria is scored 1. The market segment growth this product 
competes in (dairy nutritional products, cited as “ruminant specialties” in the Annual 
Report) is cited as growing 6.6 percent. The product life cycle position is scored as a 1 
since the product was launched in the early 2000s and sales are alluded to in the annual 
report as increasing at a decreasing rate. The product is scored a 0 for portfolio redundancy 
since it is a unique offering. Without having any information that can clearly comment on 
NPV, IRR, or ROI status of the product, a 1 score is given. The product has a 6.6 percent 
growth rate and market share is assumed to be increased due to commentary on the Animal 
Health division in the Annual Report, resulting in a 1 score for that specific criteria.  
3.6 Vaccine A and Deccox Identified as Orphan Products   
The orphan product scores for the four products analyzed are reported in Table 3.6 
Table 3.6 Orphan Product Scoring for Selected Products 
Product  Orphan Product Score 
Vaccine A 5 
Deccox 4 
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Injectable A 1 
Reashure Choline 3 
 
The scores for the four products analyzed show Deccox and Vaccine A performing 
more orphan-like than Injectable A and Reashure Choline. For this reason (because it is the 
most orphan like amongst the products analyzed) Vaccine A will be analyzed via the 
Strategy Canvas, Value Curve, Four Actions Framework, and ERIC Model process to 
determine what actions the startup could employ to make these products less orphan like 
and therefore more successful if the startup were to acquire them.  
3.7 Strategy Canvas, Value Curve, Four Actions Framework and ERIC Grid for 
Vaccine A  
For Vaccine A, the competitive forces companies in this segment are investing in 
where selected based on the product manager interview. The competitive vaccines that are 
compared to Vaccine A are kept confidential and labeled Vaccine B and Vaccine C. The 
competitive factors identified via the product manager interview are: technical support, 
ease of product use, price, and approval for use in cattle marketing programs (such as 
Select VAC® or the VAC-45 programs that provide premiums to cattle producers that use a 
select type of animal health protocols that include vaccines such as Vaccine A). These 
critical success factors are on the horizontal axis of the strategy canvas presented in Figure 
3.1 On the vertical axis is the benefit that customers receive from the product relative to the 
appropriate critical success/competitive factor. For example, a high score on Marketing 
Support for Vaccine C means that the parent company that sells Vaccine C invests in 
marketing more than Vaccine A, or Vaccine B.  
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Figure 3.1 Strategy Canvas and Value Curve for Vaccine A  
 
3.8 Application of the Four Actions Framework Resulting in an ERIC Grid and New 
Strategy Canvas and Value Curve for Vaccine A  
Once the Strategy Canvas and Value Curve for Vaccine A is completed, the Four 
Actions Framework questions are applied to help the startup think about ways to 
differentiate Vaccine A from the competition in terms of delivering new forms of customer 
value and also to understand what competitive factors could be optimized by reducing, 
increasing, or eliminating investment (The Four Actions Framework questions are: (i) 
which factors should be eliminated? (ii) which factors should be reduced? (iii) which 
factors should be raised above the industry standard?  And (iv) which factors should be 
created that the industry has not offered?).   
Answers to the four action framework questions are presented in the ERIC Grid 
(Figure 3.2).   
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Figure 3.2 The ERIC Grid for Vaccine A  
ELIMINATE 
 
 
INCREASE 
Price 
Approvals for use in cattle marketing 
programs 
REDUCE  
Technical Support  
CREATE 
Simple and disciplined tier pricing   
 
The recommendations in Figure 3.2 for Vaccine A are to increase the price and marketing 
support for the product, to reduce technical support, and to create a simple and disciplined 
tier pricing system. The recommendation to increase price is based on the knowledge that 
Vaccine C is providing customers value at a higher price with a product that does not have 
as high value on the ease of use competitive factor. The reduction of technical support 
recommendation is made based on an insight gleaned from the product manager interview 
that indicated Vaccine A is not approved for use in preconditioning programs such as 
Select VAC and VAC-45. These preconditioning programs have approved animal health 
protocols (that include specific vaccine recommendations) and Vaccine A is not always 
considered by customers. Increasing the awareness or approvals of Vaccine A as an option 
for cattle producers participating in these type of marketing programs could provide more 
value to customers.   
A value creation opportunity that is recommended is a simple and disciplined tier 
pricing system. This idea came from the interview with the product manager that indicated 
a constant source of frustration for customers that purchases vaccines is that the true price 
paid for a product is often blurred by an array of confusing rebate, charge-back, and other 
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programs offered by parent companies. A simple, two tiered pricing program – built on the 
tenet of larger volume purchases would receive a better price than smaller volume 
purchases, at levels that could be determined, is a factor customers would value. Taking 
into consideration the ERIC grid recommendations, a new value curve for Vaccine A is 
constructed (Figure 3.3).  
Figure 3.3 The New Strategy Canvas and Value Curve for Vaccine A  
 
3.9 A New Scorecard for Vaccine A  
A new scorecard is developed for Vaccine A taking into consideration the 
recommendations made as a result of applying the Four Actions Framework, and ERIC 
Grid recommendations. The scorecard is shown in Table 3.4.  The impact of 
recommendations to manage Vaccine A in a manner to deliver more customer value results 
in the product being less orphan like. By having more marketing support (by way of the 
startup deciding to increase the approvals for Vaccine A in cattle marketing programs) and 
by Vaccine A not being redundant in a portfolio (since the startup would own the product 
and not the parent company) Vaccine A decreases its orphan product score. The creation of 
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a new competitive factor (simple tier pricing) could also translate to product sales 
increasing (this is assumed to be the case in Table 3.4).  
Table 3.7 Orphan Product Score for Vaccine A Post Recommendation 
Implementation 
Orphan 
Product 
Criteria 
0 score 1 score  Vaccine A 
Initial Score 
Vaccine A 
New Score
Marketing 
support and 
focus is low  
Some marketing 
support  
No marketing 
support 
 
1 0 
Product sales 
over time are 
declining  
5-year sales 
trend is flat or 
increasing   
5-year sales trend is 
declining 
1 0 
Cash flow is 
uncertain 
Consistently 
positive cash 
flow  
Periods of cash 
flow rotating 
between positive 
and negative  
0 0 
Market growth 
is low  
Market growth 
higher than 
GDP growth 
Market growth 
lower than GDP 
growth 
0 0 
Market segment 
growth is low 
Market segment 
growing faster 
than the industry 
average 
Market growth 
growing lower than 
the industry 
average 
0 0 
Product life 
cycle position is 
mature 
Product is 
increasing sales 
at an increasing 
rate 
Product is 
increasing sales at a 
decreasing rate 
1 1 
Product is 
redundant in a 
portfolio 
Unique product 
offering 
Redundant offering 
in a portfolio  
1 0 
Product does 
not meet 
company NPV, 
IRR, or ROI 
standards 
Does not meet 
companies 
started 
benchmark 
Does meet 
companies stated 
benchmark 
0 0 
Product has low 
growth rate and 
low market 
share 
Product is 
growing faster 
than growth for 
the segment it 
competes in and 
market share is 
Product growth 
lower than the 
growth for the 
segment it 
competes in and 
market share is 
1 1 
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equal or greater 
than competitors 
lower than key 
competitors 
Total Score   5 2 
 
The impact of the recommendations on the orphan product status of Vaccine A is a 
reduction of orphan product score by 3 points. The way that the startup could reduce the 
orphan product score is by eliminating, reducing, increasing, or creating competitive factors 
as they relate to value delivered to a customer. The tradeoffs that were made, and the 
subsequent impact of these tradeoffs on the orphan product score is show in Figure 3.4. 
This matrix could be used in future orphan product acquisition scenarios to understand how 
a specific recommended action could impact orphan scoring. For Vaccine A, the 
recommendations only impacted a few factors, but were able to generate a less orphan like 
performance from the product, as evidenced by the score change.  
Figure 3.4 Impact of Recommendations on Competitive Factors  
Orphan 
Product 
Criteria 
Impact of 
Increased Price
Impact of 
Decreased 
Technical Service 
Impact of 
Increased 
Marketing 
Programs 
Impact of 
New Price 
System 
Marketing 
support and 
focus is low  
  +  
Product sales 
over time are 
declining  
+ - + + 
Cash flow is 
uncertain 
+    
Market growth 
is low  
    
Market 
segment growth 
is low 
    
Product life 
cycle position 
is mature 
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Product is 
redundant in a 
portfolio 
    
Product does 
not meet 
company NPV, 
IRR, or ROI 
standards 
    
Product has low 
growth rate and 
low market 
share 
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CHAPTER IV: CONCLUSION 
The idea that companies often lack divestiture strategies serves as a basis for the 
concept of an orphan product. This thesis has defined an orphan product as a product that 
has low marketing support/focus, is declining in sales, has uncertain cash flow, is 
competing in a market with low growth, is competing in segment with low growth, is 
mature in its product life cycle, is redundant in a portfolio, does not meet company 
financial standards, and has low market share. A startup company in the animal health 
space is looking for methods to identify orphan products for potential acquisition, and for 
recommendations on how to ensure success selling an acquired product. The definition of 
orphan product is applied to a scorecard system that can be used, in conjunction with 
primary and secondary market research, to score products based on their orphan like 
behaviors. In this thesis, four products were scored for their orphan characteristics. While 
no one product scored on each orphan criteria, there was a separation amongst products that 
had higher orphan scores (Vaccine A, and Deccox) and products that had lower orphan 
scores (Injectable A, and Reashure Choline).  
The Four Actions Framework, Strategy Canvas and Value Curve, and ERIC Grid 
methods were applied to Vaccine A, as a means to guide the strategic decisions a startup 
company would need to make to differentiate this product if it is acquired. The 
differentiation opportunities are based on investments the startup could make relative to 
factors that Vaccine A competes on with other products. Factors that were used to compare 
Vaccine A to its competitors were technical support, price, ease of use, and the ability for a 
given vaccine to compete in a value added cattle marketing program. In addition to 
recommendations made on existing factors, a new competitive factor was introduced that 
could provide value to customers and differentiate Vaccine A from its competitors. The 
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new factor is a simple price system that customers do not feel they have with current 
vaccines that compete in this space.  
The result of applying the recommendations that resulted from the analysis is a new 
orphan product score card for Vaccine A that shows a decrease in scoring relative to orphan 
product characteristics. The specific ways that the recommendations impacted the orphan 
product scoring criteria was presented as a means to show the impact investments 
recommended to the startup had on the orphan product score. For example, simply the 
purchase of the orphan product (Vaccine A) from a parent company would reduce a the 
“redundant in portfolio” score since Vaccine A, as owned by a startup, would not be in a 
portfolio anymore. Additionally, the recommendation to pursue approval for Vaccine A in 
a wider variety of cattle marketing programs would have an impact on reducing the 
“marketing support” orphan product criteria.  
This research makes the case for orphan products as undervalued products that 
could be acquired, analyzed, invested in, and marketed in ways that improve customer 
value relative to existing factors, or new factors that could be created by a startup by way of 
Blue Ocean style analysis. Further research could be conducted across a wider selection of 
products to gather more data on orphan product rankings. Additionally, research on the 
impact of investments as the result of Blue Ocean style analysis on orphan product scores 
could be pursued to provide more empirical support for concepts presented.  
  
27 
 
WORKS CITED 
 
Alexander, G. J., and J. C. Francis. 1986. Portfolio Analysis. Englewood Cliffs: Prentice-
Hall. 
 
Dranikoff, L. , T. Koller, and A. Schneider. 2002 . "Divestiture: Strategy's Missing Link." 
Harvard Business Review, Vol. 80 No. 5: 75-83. 
 
Fox, J. E. 1985. "Coccidiosis in Cattle." Modern Veterinarian Practice 113-116. 
 
Kim, W. Chan, and Renee Mauborgne. 2005. Blue Ocean Strategy. Boston: Harvard 
Business School Publishing. 
 
Kotler, P., and K. Keller. 2006. Marketing Management. Prentice-Hall. 
 
Mankins, Michael C. 2008. "How the Best Divest." Harvard Business Review, October. 
 
Prestige Brands Holdings, Inc. 2005. "Annual Report." Annual Report, Irvington. 
 
Research and Markets. 2014. North American Anticoccidial Drugs Market-Global Trends 
and Forecasts- 2014-2019. Market Research Report , Dublin: Research and 
Markets. 
 
Roucan-Kane, Maud, and Whitney O. Peake. 2007. Milking the most from your 
promotional dollar: an analysis of agribusiness firms serving U.S. agricultural 
producers. Working Paper #07-05, LaFayette: Department of Agricultural 
Economics. 
 
Wind, Y., and H. J. Claycamp. 1976. "Planning product line strategy: a matrix approach." 
Journal of Marketing 2-9. 
 
 
 
